SQZ Biotechnologies Company (SQZ)
| Market Cap | 339.37M |
| Revenue (ttm) | 18.60M |
| Net Income (ttm) | -64.42M |
| Shares Out | 27.92M |
| EPS (ttm) | -3.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,004 |
| Open | 12.15 |
| Previous Close | 12.24 |
| Day's Range | 12.00 - 12.27 |
| 52-Week Range | 11.15 - 36.49 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 36.25 (+198.4%) |
| Est. Earnings Date | Nov 10, 2021 |
About SQZ
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develop...
Financial Performance
In 2020, SQZ's revenue was $21.00 million, an increase of 4.42% compared to the previous year's $20.11 million. Losses were -$50.52 million, 56.9% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SQZ stock is "Strong Buy." The 12-month stock price forecast is 36.25, which is an increase of 198.35% from the latest price.
News
SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present updates...
SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be pres...
SQZ Biotechnologies to Present at Cantor Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be pres...
SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the first clinical tran...
SQZ Biotechnologies to Present at Upcoming Health Care Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be pres...
SQZ Biotechnologies Reports Second Quarter 2021 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2021 financial...
SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the appointments of Bernard ...
SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem C...
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical regenera...
SQZ Biotechnologies' TAC Program Induces Multiple Mechanisms Of Antigen-Specific Tolerance, Animal Study Shows
SQZ Biotechnologies Company (NYSE: SQZ) has announced preclinical results from its Tolerizing Antigen Carrier (TAC) program, showing potential for application in various autoimmune diseases. Data will b...
SQZ Biotechnologies Tolerizing Antigen Carrier (TAC) Program Induces Antigen-Specific Immune Tolerance in Preclinical...
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, is presenting preclinical results fr...
SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate I...
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results from...
SQZ Biotech to Present at Jefferies Virtual Health Care Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be part...
SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from O...
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, will present safety and tolerability, manuf...
SQZ Biotechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported financial results for the pe...
SQZ Biotech to Present at BofA Securities 2021 Virtual Health Care Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participatin...
SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing Capabilities and Advantages in Cell Perfo...
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced today that it will present new data on th...
SQZ Biotech Presents Preclinical Data on its mRNA-based enhanced APCs and the Potential of the SQZ APC Platform in KR...
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today shared preclinical data from its next generat...
SQZ Biotech to Participate in April Investor Events
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participatin...
SQZ Biotechnologies Reports 2020 Financial Results and Recent Advancements
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and...
SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs at the American Associati...
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present ...
Should You Buy SQZ Biotechnologies Company (SQZ) Ahead of Earnings?
SQZ Biotechnologies Company (SQZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief execut...
Why SQZ Biotechnologies Sank on Friday
The cell-squeezing specialist priced a new stock issue.
SQZ Biotechnologies Under Pressure After $60M Equity Raise At 9% Discount
SQZ Biotechnologies Co (NYSE: SQZ) prices its underwritten public offering of 3 million common shares at $20 per share. Underwriters have an option to purchase up to an additional 450,000 shares.
SQZ Biotech Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that it has commenc...